AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04289701 — intervention group
Intervention type: OTHER
Intervention: Health Services for Systematic Hypertension Management
Description: The systematic hypertension management health services from the Hypertension prevention and control initiative in China project. Main services are as follows:~1. Healthcare provider training and patient education.~2. Standardized guideline-based hypertension diagnosis, treatment and management recommendation.~3. Patient-centered, pan-cycle continuous hypertension management via the organizing framework of NMAH and sharing digital platform.~4. Periodical Patient follow-up via blood pressure monitor-sharing system and in collaboration with other basic local public health programs.~5. Outcome and performance evaluation quarterly.~6. Incentives for healthcare organizations and primary healthcare providers, and subsidies to patients.~7. Certification for Honorary Hypertension Centers at county levels and establishment for hypertension clinics at primary care centers.
Study NCT04025437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy alone
Description: Patients in this group will receive hepatectomy alone.
Study NCT04025437 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant radiotherapy
Description: Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
Study NCT02396537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Administered intranasally prior to Midazolam administration.
Study NCT02396537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
Study NCT02396537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
Study NCT02396537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Administered intranasally prior to Midazolam administration.
Study NCT03774602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion and provision of RMNCH services
Description: Implementation of quality, high-impact interventions at institutional and community levels to increase access to and utilization of RMNCH services
Study NCT03361787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parentship- a multi dimensional intervention program to improve parental resilience
Description: Parentship is a multi dimensional intervention program to improve parental resilience and adolescent participation using the OPC model.
Study NCT02534753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascor L 500® (Ascorbic Acid Injection, USP)
Description: A sterile, solution containing 500 mg ascorbic acid per mL
Study NCT03056664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine drainage surgery
Study NCT03056664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC injection 01
Description: Local MSC injection in peri-anal with a dose of 3×10E6/kg
Study NCT03056664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC injection 02
Description: Local MSC injection in peri-anal with a dose of 6×10E6/kg
Study NCT03056664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: NS injection instead of MSC
Study NCT04239729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Website and Coaching
Description: The ACT website includes sixteen sessions and is designed to teach a series of skills from ACT applied to hoarding. The intervention also includes brief supportive coaching (an initial phone call and weekly support over email).
Study NCT02199821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula with soybean oil, medium-chain triglycerides
Study NCT02199821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean oil formula commonly used in the hospital
Study NCT02372760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BA by spray catheter (Olympus PW-205V)
Description: This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V)
Study NCT02372760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BA classic anesthesia
Description: This group will have the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
Study NCT02372760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: Both groups will receive lidocaine as the anesthesia for bronchoscopy
Study NCT02372760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia
Description: Both groups will receive lidocaine as the anesthesia for bronchoscopy
Study NCT00150995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Study NCT03861520 — intervention group
Intervention type: DEVICE
Intervention: Midtrimester anomaly scan
Description: A detailed anomaly scan to detect soft markers at 16 to 24 weeks pregnancy
Study NCT03861520 — intervention group
Intervention type: GENETIC
Intervention: Fetal Karyotyping
Description: Fetal karyotyping after birth to confirm chromosomal anomaly diagnosed clinically
Study NCT01842737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal treatment
Description: This treatment will be applied to the low back region only. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. After carefully helping the participant into the proper position, the doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During this procedure, the participant may feel and/or hear a popping sound. After treatment, the doctor may ask the participant to rest on the table for a few moments. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
Study NCT01842737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: The study doctor will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
Study NCT02732626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Study NCT02732626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Study NCT03697382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very Low Steps
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Very Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
Study NCT03697382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Steps
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
Study NCT03697382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Steps
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Moderate Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
Study NCT02918734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobutton CL BTB
Description: ACL reconstruction with Endobutton CL BTB
Study NCT02918734 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal interference screw
Description: ACL reconstruction with metal interference screw
Study NCT03360877 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health-care associated infection (HCAI)
Description: Cleaning of the child with soap and water administered by the child's accompanying person in a structure or - a cleaning of the child with chlorhexidine gluconate administered by the child's accompanying person in the other structure
Study NCT01884714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/high calorie meal
Description: All subjects are provided a high calorie (\~1300kcal) and high fat (\~60g fat) breakfast meal.
Study NCT04619953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Postural Stability Training
Description: The dynamic postural stability training, will consist of marching on unstable surface and on treadmill both with open and with closed eyes.
Study NCT04619953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Motor Training
Description: The cognitive-motor training consisted of a dual task paradigm: each patient was asked to walk without stopping and was explained that, during the task, they might hear a sound, and in that case, they should have look at the stimulus 'side and recognize a visual target. This dual task was performed both marching on an unstable surface and marching on treadmill.
Study NCT04619953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: The conventional neuromotor rehabilitation will consist in muscles stretching, active-assisted mobilizations, neuromuscular facilitations, gait training and balance exercises using swinging platforms
Study NCT00335686 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
Description: Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
Study NCT00335686 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Nevirapine (Viramune): 1 comp (200mg)/12h
Description: Nevirapine (Viramune): 1 comp (200mg)/12h
Study NCT04164498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: exposure to music to investigate its effects on reducing noise adverse effects
Study NCT02388932 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT02696044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triheptanoin
Description: Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.
Study NCT02608905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
Study NCT02608905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
Study NCT02492113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Description: Titrated-PEEP. After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged.
Study NCT02492113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ZEEP
Description: After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at PEEP = 0-5 cmH2O, with the PSV=0 and FiO2 unchanged.
Study NCT03881319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional gynecologic treatment
Description: Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
Study NCT03881319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low dose acupuncture
Description: Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
Study NCT02388932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT02388932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT03200730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Dignity Intervention group
Description: A brief psychotherapeutic intervention offered to a family dyad (i.e., patient and one identified family caregiver) using narrative approach with life review elements. The purpose is to facilitate an open dialogue between the family dyad that strengthens family connectedness and emotional connection.
Study NCT02529124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: Maltodextrin (generic) in powder form, flavoured and instantised to be dissolved in water.
Study NCT02529124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PROTEIN
Description: The milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.
Study NCT02529124 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL ACTIVITY
Description: A structured, progressive programme of exercises using resistance exercise bands supervised by clinical therapists undertaken three times per week for 24 weeks of the intervention.
Study NCT02388932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03881319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose acupuncture
Description: Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner Pass(PC6) 、Supreme Rush(LR3) 、Joining Valley(LI4) 、Supreme Stream(KI3) 、Uterus(EX-CA1) 、Leg Three Miles(ST36)
Study NCT01486134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multipolar Radiofrequency ablation
Description: Percutaneous multipolar radiofrequency ablation.
Study NCT00745238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: withdrawal of non-invasive ventilation
Description: Four weeks withdrawal of non-invasive ventilation
Study NCT03565640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capio Slim Device
Description: Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Capio Slim Device.
Study NCT03565640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anchorsure Device
Description: Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Anchorsure Device.
Study NCT00454220 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 33 patients to placebo + 131-I arm
Study NCT00454220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRrhTSH
Description: 33 patients to 0.01 mg MRrhTSH + 131-I arm
Study NCT00454220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRrhTSH
Description: 33 patients to 0.03 mg MRrhTSH + 131-I arm
Study NCT00402558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 1.5 mg/kg By Vein Daily x 3 Days
Study NCT00402558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/m\^2 By Vein Over 3 Hours x 4 Days
Study NCT00402558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 By Vein Over 30 Minutes x 4 Days
Study NCT00402558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alloreactive NK Infusion
Description: Alloreactive NK infusion from haploidentical donor on Day -8. The alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7.
Study NCT00402558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 x 109/L for 3 consecutive days.
Study NCT00402558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose of 0.015 mg/kg as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present.
Study NCT00402558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 intravenously on Days 1, 3 and 6 and Day +11 post transplant.
Study NCT00402558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4 only to participants receiving fourth dose level of NK cells.
Study NCT01993953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BodyPump
Description: Participants will be offered BP sessions at fitness centers in Oslo/Akershus. They will exercise three times a week. The instructors at all centers have a BP license from Les Mills, and the same program will be conducted at all centers at all times. The project manager has been in contact with Les Mills Scandinavia and has been given permission to use the training concept for research.
Study NCT01993953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personal training
Description: Participants in this group will be offered training with a PT at the Norwegian School of Sports Sciences. They will exercise with their PT three times per week. The training program for this group will be based on the exercises in the BP class, but repetitions will vary between 3-15, and series between 2-4.
Study NCT01993953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training with instructor
Description: Participants in this group will be invited to train on their own, three times a week, at the Norwegian School of Sports Science. Prior to the intervention period they will receive a training manual, instructions of the exercises and advice about progression during the intervention period. They will also have a follow-up with the same instructor after six weeks. The training program for this group will be the same as for group B. The PT's from group B will also serve as training instructors.
Study NCT03376308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Score
Description: Four poin scala 0=No Pain~1. mild~2. intermediate~3. severe
Study NCT03376308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Withdrawal movement score
Description: Withdrawal movements~1. no movement response~2. movement limited to the wrist~3. movement limited to the elbow/shoulder,~4. generalized movement response.
Study NCT03376308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hemodynamic response
Description: Hemodynamic data were recorded in the patients taken in the operation room. (T0). Hemodynamic values (T1) measured 1 minute after administration of intravenous propofol were recorded. Hemodynamic values (T2) measured 1 minute after administration of intravenous rocuronium were recorded. Hemodynamic values (T3) measured 1 minute after administration of endotracheal intubation were recorded.
Study NCT03316469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: 100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods
Study NCT03316469 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follicular growth
Description: Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.